Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of Rituximab combined
with chemotherapy in CD20+ adult acute lymphoblastic leukemia.